2018 NCAP Chronic Care & Health-System Practice Forums Meeting
The Great Wolf Lodge
Concord, North Carolina
March 21-23, 2018
Developed with UNC Eshelman School of Pharmacy
Co-Sponsored by Campbell University College of Pharmacy
Health Sciences
Fred Wilson High Point University School of Pharmacy
Wingate University School of Pharmacy
Wednesday, March 21
5:00-7:00 pmNetworking Reception with Exhibitors
Thursday, March 22
7:00-8:15 amRegistration/Breakfast with Exhibitors
8:15-8:30Welcome/Introductions – Grand Plenary Until 3:30 PM
Moderators:
Jason M. Moss, PharmD, BCGP
Assistant Professor, Pharmacy Practice
Campbell University College of Pharmacy
and Health Sciences
Clinical Pharmacy Specialist
Durham VA GRECC
Chair, NCAP Chronic Care Practice Forum
Kira Brice Harris, PharmD, BCPS, CDC, CPP
Associate Professor
Wingate University School of Pharmacy
Chair, NCAP Health-System Practice Forum
8:30-9:30ACPE#: 0046-9999-18-056-L04-P (1.0hr)
ACPE#: 0046-9999-18-056-L04-T (1.0 hr)
“In Managing Change or Conflict, What is Needed”
Learning objectives for Pharmacists/Technicians:
At the completion of this knowledge-based activity, the
participant will be able to:
1) Identify what is needed to manage change
and not create conflict
2) Identify and understand the five dysfunctions of a
team
3) Apply change and conflict management
with staff, clients and contracts
Eric Miller
President
Smart Performance Strategies, Inc.
9:30-10:30ACPE#: 0046-9999-18-057-L04-P (1.0 hr)
ACPE#: 0046-9999-18-057-L04-T(1.0 hr)
“Collaborative Practice Authority: An Update on
Advocating for Change”
Learning objectives for Pharmacists/Technicians:
At the completion of this knowledge-based activity, the
participant will be able to:
1) Define the current status of NCAP advocacy agenda
on collaborative practice authority
2) Describe how the current collaborative practice
authoritystatute creates barriers to innovative
practice and patient care
3) List the elements of a new bill designed to broaden
collaborative practice in North Carolina
4) Create a personalized action plan for engagement
on this issue(Pharmacist only objective)
Penny S. Shelton, PharmD
Executive Director
NC Association of Pharmacists
10:30-10:45Break
10:45-11:45ACPE#: 0046-9999-18-058-L01-P (1.0hr)
ACPE#: 0046-9999-18-058-L01-T (1.0hr)
Clinical Updates and Therapeutic Controversies
Related to the Use of Direct Oral Anticoagulants (DOAC)
Learning objectives for Pharmacists/Technicians:
At the completion of this knowledge-based activity, the
participant will be able to:
1) Review role of DOAC pharmacotherapy in the
management of atrial fibrillation (AFib) and venous
thromboembolism (VTE)
2) Appraise recently published literature outlining
clinical applicability of DOAC pharmacotherapy
3) Identify criteria for fringe DOAC candidacy and
available clinical data which drives decision-making
4) Analyze patient case scenarios to determine most
appropriate anticoagulant strategy and duration
of selected therapy
Robert Tunney, PharmD, BCPS
Clinical Pharmacy Specialist
ECHI Heart Failure Program
Vidant Medical Center
Clinical Assistant Professor, Pharmacy Practice
Campbell University College of Pharmacy & Health
Sciences
11:45-1:15Lunch Symposium
UAN#: 0468-0000-18-001-L01-P (1.0 hr)
UAN#: 0468-0000-18-001-L01-T (1.0 hr)
“Acute Coronary Syndrome: Getting to the Heart
of the Matter for Pharmacists”
Learning objectives for Pharmacists/Technicians:
At the completion of this application-based activity, the
participant will be able to:
1) Identify patients at risk for ACS
2) Explain the distinct phases of the continuum of
ACS: UA, NSTEMI, and STEMI in order to assist
the care team in managing patients as they progress
through treatment
3) Summarize best practices to counsel patients on
the importance of adherence and follow-up care
while monitoring their ongoing health including
coordinating all their prescriptions
Toby C. Trujillo, PharmD, FCCP, FAHA,
BCPS-AQ Cardiology
Associate Professor
University of Colorado Skaggs School of Pharmacy
Pharmaceutical Sciences
University of Colorado Anschutz Medical Campus
Clinical Specialist – Anticoagulation/Cardiology
University of Colorado Hospital
Denver, Colorado
The Medical Learning Institute, Inc.is accredited by
The Accreditation Council for Pharmacy Education as a
provider of continuing pharmacy education.
1:15-2:15ACPE#: 0046-9999-18-059-L01-P (1.0 hr)
ACPE#: 0046-9999-18-059-L01-T (1.0 hr)
“Updates in an Oft Neglected Disease State” Learning objectives for Pharmacists/Technicians:
At the completion of this knowledge-based activity, the
participant will be able to:
1) Compare and contrast GOLD 2017 with previous
GOLD Guidelines
2) Assess the severity of a patient’s COPD and
recognize an acute exacerbation of COPD
3) Recommend patient specific interventions based
on risk factors, status/severity, and progression
of COPD(Pharmacist only objective)
4) Develop and justify a patient specific
pharmacotherapy care plan for both the management
and acute exacerbations of COPD
J. Andrew Woods, PharmD, BCPS
Associate Professor of Pharmacy
Wingate University School of Pharmacy
Internal Medicine Clinical Pharmacy Specialist
Carolinas Medical Center - Main
2:15-3:15ACPE#: 0046-9999-18-060-L01-P (1.0 hr)
ACPE#: 0046-9999-18-060-L01-T (1.0 hr)
“Beyond Statins: Managing Hyperlipidemia and
Reducing Cardiovascular Risk”
Learning objectives for Pharmacists/Technicians:
At the completion of this knowledge-based activity, the
participant will be able to:
1) Compare and contrast recommendations from
major guidelines for the management of Hyperlipidemia
2) Evaluate the cardiovascular benefits of alternative
treatment options based on current literature
3) Evaluate a patient case to determine cardiovascular
risk and appropriate treatment strategies
Kira Brice Harris, PharmD, BCPS, CDC, CPP
Associate Professor
Wingate University School of Pharmacy
Chair, NCAP Health-System Practice Forum
3:15-3:30Break
3:30-5:30Concurrent Sessions:
(A) ACPE#: 0046-9999-18-061-L01-P (2.0 hrs)
ACPE#: 0046-9999-18-061-L01-T (2.0 hrs)
“New Drug Update”
Learning objectives for Pharmacists/Technicians:
At the completion of this knowledge-based activity, the
participant will be able to:
1) Identify new FDA approved drugs that have been
approved in the past 12 months that are pertinent
to long-term care
2) Discuss the indication, mechanism of action, side
effect profile, monitoring, dosing and special
administration instructions of each medication
3) If applicable - review any clinical trials or studies
comparing the new medication to similar drugs in
its therapeutic class
4) Discuss cost and feasibility options of new drugs
Bobbie H. Hall, PharmD, CGP
Consultant Pharmacist
Pharmacy Education Coordinator
Neil Medical Group Pharmacy Services Division
(B) ACPE#: 0046-9999-18-062-L04-P (2.0 hrs)
ACPE#: 0046-9999-18-062-L04-T (2.0 hrs)
“Health-System Round Tables”
Learning objectives for Pharmacists/Technicians:
At the completion of this knowledge-based activity, the
participant will be able to:
1) Describe current gaps in practice across North Carolina
2) Discuss pharmacy practices to empower pharmacists
3) Describe systems to improve patient care
Round Table Topics and Facilitators Listed in APP
Friday, March 23rd
7:45-8:00Welcome/Introductions – Grand Plenary Until 9:00 AM
Moderators:
Jason M. Moss, PharmD, BCGP
Assistant Professor, Pharmacy Practice
Campbell University College of Pharmacy
and Health Sciences
Clinical Pharmacy Specialist
Durham VA GRECC
Chair, NCAP Chronic Care Practice Forum
Kira Brice Harris, PharmD, BCPS, CDE, CPP
Associate Professor
Wingate University School of Pharmacy
Chair, NCAP Health-System Practice Forum
8:00-9:00Breakfast Symposium
UAN#: 0473-9999-18-001-L01-P (1.0 hr)
“The Challenge of Clostridium difficile and
Antimicrobial-Resistant Gram-negative Infections:
Opportunities to Re-Evaluate Current Management
Approaches”
Learning objectives for Pharmacists:
At the completion of this knowledge-based activity, the
participant will be able to:
1) Explain current trends in antimicrobial resistance and
identifypatient risk factors for infection
2) Assess the role of newer antimicrobial agents as part
of the armamentarium in the management of infections
caused by multidrug-resistant Gram-negative bacteria and C.difficile
3) Evaluate the utility of novel approaches that reduce
the risk of recurrent C. difficile infection in high-risk
patients
4) Describe antimicrobial stewardship strategies that aim to minimize the burden of serious bacterial
infections in healthcare institutions
James S. Lewis, II, PharmD, FIDSA
ID Clinical Pharmacy Coordinator & Adjunct
Associate Professor
Departments of Pharmacy & Infectious Diseases
Oregon Health & Science University – Portland
(A)Chronic Care Practice Forum Plenary
9:15-10:15ACPE#: 0046-9999-18-063-L04-P (1.0 hr)
ACPE#: 0046-9999-18-063-L04-T (1.0 hr)
“Reform of Requirements for Long-Term Care
Facilities: The Mega-Rule…Pharmacy Impacts”
Learning objectives for Pharmacists/Technicians:
At the completion of this knowledge-based activity, the
participant will be able to:
1) Discusspharmacy-related Phase 1 requirements
2)Discusspharmacy-related Phase 2 requirements
and associated guidance
3) Discussother important pharmacy-related changes to Appendix PP and associated guidance
4) Brieflydescribe pharmacy-related Phase 3
requirements
Todd King, PharmD, CGP
Director Clinical Services, LTC
Omnicare, A CVS Health Company
10:15-11:15ACPE#: 0046-9999-18-064-L02-P (1.0 hr)
ACPE#: 0046-9999-18-064-L02-T (1.0 hr)
“Going Viral: HIV Update – 30 Years of Progress”
Learning objectives for Pharmacists/Technicians:
At the completion of this knowledge-based activity, the
participant will be able to:
1) Reviewthe epidemiology of HIV in the United
States
2) List the various classes and agents of antiretroviral
therapy
3) Describe the initial recommended treatment options
for most adult patients with HIV
4) Identify which adult patients would be candidates
for pre-exposure prophylaxis (PrEP)
5) Summarize investigational treatment options for HIV
Steven W. Johnson, PharmD, BCPS, CPP, AAHIVP
Assistant Professor, Department of Pharmacy Practice
Campbell University College of Pharmacy & Health
Sciences
11:15-11:30Break
11:30-12:30ACPE#: 0046-9999-18-065-L01-P(1.0 hr)
ACPE#: 0046-9999-18-065-L01-T (1.0 hr)
“De-Intensification of Disease Management at the End
of Life – When Why and How”
Learning objectives for Pharmacists/Technicians:
At the completion of this knowledge-based activity, the
participant will be able to:
1) Discussthe stages that a terminally ill patient
will go through prior to death
2)Identify the disease states most likely in need of
de-intensification at the end of life
3) Describe the intersection between the
patient/HPCOA goals of care and appropriate disease
management
4)Discuss medication tapering at the end of life
and which medication classes require it
5) Summarizecreative medication
administration techniques employed by the hospice
provider for the dying patient
Jeff Lynds, RPh
Director of Pharmacy
Hospice & Palliative Care Charlotte Region
12:30-12:45Closing Remarks and Farewell
12:45-untilJoint Executive Committee Working Lunch
********************************************************************************************
(B) Health-System Practice Forum Plenary
9:15-10:15ACPE#: 0046-9999-18-066-L04-P (1.0 hr)
ACPE#: 0046-9999-18-066-L04-T (1.0 hr)
“Innovative Practice Models Across the Care Continuum
A Panel Discussion of a Substance Abuse Patient Care”
Learning objectives for Pharmacists/Technicians:
At the completion of this knowledge-based activity, the
participant will be able to:
1) Explore innovative pharmacy practice models in the
inpatient, outpatient and transitional settings
2) Identify barriers and solutions to optimal patient care
in all practice settings
3) Apply innovative practice solutions to a patient case
to discuss the opioid abuse epidemic
Ryan Owenby, PharmD
Clinical Pharmacy Specialist, Emergency Medicine
Durham VA Medical Cente4r
Courtenay Gilmore Wilson, PharmD, CDE, BCACP,
BCPS, CPP
Associate Director of Pharmacotherapy
Mountain Area Health Education Center
Assistant Professor of Clinical Education
UNC Eshelman School of Pharmacy
PGY2 Residency Director
MAHEC/UNC Eshelman School of Pharmacy
10:15-11:15ACPE#: 0046-9999-18-067-L04-P (1.0 hr)
ACPE#:0046-9999-18-067-L04-T (1.0 hr)
“Anatomy of a Medical Malpractice Case”
Learning objectives for Pharmacists/Technicians:
At the completion of this knowledge-based activity, the
participant will be able to:
1) Reviewthe process leading to a medical lawsuit
2) Identifythe three common motivations for
medical malpractice cases
3) Discuss the legal implications of collaborative
medicine
4) Compare and contrast policy and procedure vs.
standard of care
5)Describethe importance of chain of command as
applied to pharmacist liability
6) Articulate the legal necessity of appropriate
documentation
7) Reviewthe legal aspects of the employer/
employee relationship
Tricia MorvanDerr, BA, J.D.
Managing Member
Lincoln Derr PLLC
Charlotte, North Carolina
11:15-11:30Break
11:30-12:30ACPE#: 0046-9999-18-068-L04-P (1.0 hr)
ACPE#: 0046-9999-18-068-L04-T (1.0 hr)
“Standardized Concentrations for Oral Liquid
Medications”
Learning objectives for Pharmacists/Technicians:
At the completion of this knowledge-based activity, the
participant will be:
1) Discuss the reason for a National standard for oral
liquid medications
2) Review the process for choosing the recommended
standard
3) Describe the ramifications from insurance
companies once a national standard is set
Elizabeth Farrington, PharmD, FCCP, FCCM, FPPAG, BCPS
Pharmacist III – Pediatrics
New Hanover Regional Medical Center
Department of Pharmacy
12:30-12:45Closing Remarks and Farewell